GOSS

Gossamer Bio, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-17

Figures on this page computed 2026-11-08 12:40 UTC

Last close

9.95USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-17

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
The filing itself
-351.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
-353.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.10 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.19x

1.18x

1.41x

n/a

0.02x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales1.19x
Its own average over 4 years, 40.8M.
Profit1.18x
Its own average over 10 years, -144.8M.
Free cash flow1.41x
Its own average over 9 years, -121.3M.
Debtn/a
Its own average over 7 years, 23.7M.
Price0.02x
Its own average over 8 years, 560. Market data, 2026-11-04

Price is furthest from its own average, at 0.02 times.

Sales is 1.19 times its own 4-year average; Profit is 1.18 times its own 10-year average; Free cash flow is 1.41 times its own 9-year average; Price is 0.02 times its own 8-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales against its own 4-year average1.19
Source
filed
Statement
income
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
The filing itself
Profit against its own 10-year average1.18
Source
filed
Statement
income
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
The filing itself
Free cash flow against its own 9-year average1.41
Source
filed
Statement
income
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
The filing itself
Debt against its own 7-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001728117-26-000017
Reported in
USD
The filing itself
Price against its own 8-year average0.02Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD